CT-4201 is a serotonergic psychedelic which is under development for the treatment of major depressive disorder. It is a prodrug of the tryptamine psychedelic psilocin that is said to have improved pharmacokinetic properties compared to psilocybin, the primary active constituent of psilocybin-containing mushrooms. CT-4201 is being developed by CaaMTech. As of November 2024, it is in the preclinical research stage of development.
See also Substituted tryptamine List of investigational hallucinogens and entactogens EB-002, MSP-1014, RE-109 (4-GO-DMT) Luvesilocin (4-GO-DiPT)
References